Cellular Biomedicine Group Inc (NASDAQ:CBMG) was the target of a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 495,400 shares, a decline of 8.7% from the May 30th total of 542,600 shares. Based on an average daily volume of 37,000 shares, the short-interest ratio is currently 13.4 days. Currently, 4.5% of the shares of the company are short sold.
A number of research firms have recently commented on CBMG. Cantor Fitzgerald set a $33.00 price objective on Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, June 25th. BidaskClub upgraded Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Cellular Biomedicine Group currently has an average rating of “Hold” and an average price target of $27.50.
Several institutional investors have recently bought and sold shares of CBMG. BNP Paribas Arbitrage SA grew its position in Cellular Biomedicine Group by 1,641.8% during the first quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the biotechnology company’s stock worth $42,000 after buying an additional 2,315 shares in the last quarter. Metropolitan Life Insurance Co. NY acquired a new stake in Cellular Biomedicine Group during the fourth quarter worth about $81,000. Rhumbline Advisers grew its position in Cellular Biomedicine Group by 49.2% during the fourth quarter. Rhumbline Advisers now owns 15,377 shares of the biotechnology company’s stock worth $272,000 after buying an additional 5,074 shares in the last quarter. Bank of New York Mellon Corp grew its position in Cellular Biomedicine Group by 16.3% during the fourth quarter. Bank of New York Mellon Corp now owns 37,857 shares of the biotechnology company’s stock worth $669,000 after buying an additional 5,308 shares in the last quarter. Finally, MetLife Investment Advisors LLC acquired a new stake in Cellular Biomedicine Group during the fourth quarter worth about $110,000. Institutional investors and hedge funds own 17.87% of the company’s stock.
Cellular Biomedicine Group (NASDAQ:CBMG) last posted its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.06. The business had revenue of $0.05 million for the quarter. Cellular Biomedicine Group had a negative return on equity of 42.41% and a negative net margin of 17,921.62%. As a group, equities analysts expect that Cellular Biomedicine Group will post -2.08 EPS for the current year.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.
Recommended Story: Why is insider trading harmful?
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.